Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A late-stage trial of epcoritamab plus R-CHOP cut the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients compared to R-CHOP alone. This marks the first bispecific antibody combination to significantly improve progression-free survival in first-line DLBCL — a major milestone for Genmab and AbbVie's jointly developed immune therapy.
Genmab and AbbVie just delivered a big win in blood cancer treatment. Their late-stage trial showed that combining epcoritamab with the standard chemotherapy regimen R-CHOP cut the risk of disease progression or death by 51% in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) — the most common form of non-Hodgkin lymphoma. The safety profile of the combo was consistent with what's already known for each therapy individually.
Epcoritamab is a bispecific antibody — an immune-based therapy that recruits the body's own T cells to attack cancer cells. While it's already approved for relapsed or refractory DLBCL, it has not yet been cleared for newly diagnosed, treatment-naïve patients, making this trial result a critical step toward expanding its use.
By the Numbers:
Why it matters: DLBCL is the most common type of non-Hodgkin lymphoma, and R-CHOP has been the standard of care for decades. A combination that meaningfully improves on that benchmark could reshape frontline treatment and represents a major clinical opportunity for patients and providers alike.
